Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan-Feb;11(1):34-43.
doi: 10.1021/cc800185z.

Distributed Drug Discovery, Part 3: using D(3) methodology to synthesize analogs of an anti-melanoma compound

William L Scott  1 , Christopher O Audu, Jeffery L Dage, Lawrence A Goodwin, Jacek G Martynow, Laura K Platt, Judith G Smith, Andrew T Strong, Kirk Wickizer, Eric M Woerly, Martin J O'Donnell
Affiliations

Distributed Drug Discovery, Part 3: using D(3) methodology to synthesize analogs of an anti-melanoma compound

William L Scott et al. J Comb Chem. 2009 Jan-Feb.

Abstract

For the successful implementation of Distributed Drug Discovery (D(3)) (outlined in the accompanying Perspective), students, in the course of their educational laboratories, must be able to reproducibly make new, high quality, molecules with potential for biological activity. This article reports the successful achievement of this goal. Using previously rehearsed alkylating agents, students in a second semester organic chemistry laboratory performed a solid-phase combinatorial chemistry experiment in which they made 38 new analogs of the most potent member of a class of antimelanoma compounds. All compounds were made in duplicate, purified by silica gel chromatography, and characterized by NMR and LC/MS. As a continuing part of the Distributed Drug Discovery program, a virtual D(3) catalog based on this work was then enumerated and is made freely available to the global scientific community.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Compounds inducing apoptosis in a melanoma cell line.
Scheme 1
Scheme 1. General Route to Analogs 8 of Anti-Melanoma Compounds
Figure 2
Figure 2
Representative analytical results for the crude and purified analog 8{15}a.
See this image and copyright information in PMC

References

    1. See preceding Perspective:

    2. Scott W. L.; O’Donnell M. J. J. Comb. Chem. 2009, 11, 3–13. - PMC - PubMed

    1. See preceding article:

    2. Scott W. L.; Alsina J.; Audu C. O.; Babaev E.; Cook L.; Dage J. L.; Goodwin L. A.; Martynow J. G.; Matosiuk D.; Royo M.; Smith J. G.; Strong A. T.; Wickizer K.; Woerly E. M.; Zhou Z.; O’Donnell M. J. J. Comb. Chem. 2009, 11, 14–33. - PMC - PubMed
    1. Dothager R. S.; Putt K. S.; Allen B. J.; Leslie B. J.; Nesterenko V.; Hergenrother P. J. J. Am. Chem. Soc. 2005, 127, 8686–8696. - PubMed
    1. Gao M.; Kong D.; Clearfield A.; Miller K. D.; Sledge G. W.; Zheng Q.-H. Synthesis 2006, 2301–2304.

    1. For recent melanoma reviews, see:

    2. Markovic S. N.; Erickson L. A.; Rao R. D.; Weenig R. H.; Pockaj B. A.; Bardia A.; Vachon C. M.; Schild S. E.; McWilliams R. R.; Hand J. L.; Laman S. D.; Kottschade L. A.; Maples W. J.; Pittelkow M. R.; Pulido J. S.; Cameron J. D.; Creagan E. T. Mayo Clinic Proc. 2007, 82, 364–380. - PubMed
    3. Markovic S. N.; Erickson L. A.; Rao R. D.; Weenig R. H.; Pockaj B. A.; Bardia A.; Vachon C. M.; Schild S. E.; McWilliams R. R.; Hand J. L.; Laman S. D.; Kottschade L. A.; Maples W. J.; Pittelkow M. R.; Pulido J. S.; Cameron J. D.; Creagan E. T. Mayo Clinic Proc. 2007, 82, 490–513. - PubMed

Publication types

MeSH terms

Substances